CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the Company sponsored the first-ever Angelman Syndrome Biomarkers & Outcome Measures Consortium at the University of South Florida (USF), in Tampa, Florida. The one-day symposium, held on March 7, 2016 focused on the advent of reliable markers and clinical measures of Angelman syndrome (AS) for the development, evaluation and registration of innovative diagnostics and therapeutics. The meeting brought together leading researchers and clinicians from the Angelman syndrome community, AS families, representatives from the Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST), and industry leaders from six companies.
